

Interview Summary	Application No. 09/380,310	Applicant(s) UKAI ET AL.	
	Examiner Mina Haghighatian	Art Unit 1616	

All participants (applicant, applicant's representative, PTO personnel):

(1) Mina Haghighatian.

(3) Nichael Hartley.

(2) E. Perez.

(4) _____.

Date of Interview: 18 November 2003.

Type: a) ☐ Telephonic b) ☐ Video Conference
c) ☒ Personal [copy given to: 1) ☐ applicant 2) ☒ applicant's representative]

Exhibit shown or demonstration conducted: d) ☐ Yes e) ☐ No.
If Yes, brief description: _____.

Claim(s) discussed: All.

Identification of prior art discussed: All.

Agreement with respect to the claims f) ☐ was reached. g) ☒ was not reached. h) ☐ N/A.


Substance of Interview including description of the general nature of what was agreed to if an agreement was reached, or any other comments: See below.

(A fuller description, if necessary, and a copy of the amendments which the examiner agreed would render the claims allowable, if available, must be attached. Also, where no copy of the amendments that would render the claims allowable is available, a summary thereof must be attached.)

THE FORMAL WRITTEN REPLY TO THE LAST OFFICE ACTION MUST INCLUDE THE SUBSTANCE OF THE INTERVIEW. (See MPEP Section 713.04). If a reply to the last Office action has already been filed, APPLICANT IS GIVEN ONE MONTH FROM THIS INTERVIEW DATE, OR THE MAILING DATE OF THIS INTERVIEW SUMMARY FORM, WHICHEVER IS LATER, TO FILE A STATEMENT OF THE SUBSTANCE OF THE INTERVIEW. See Summary of Record of Interview requirements on reverse side or on attached sheet.

Mr. Perez discussed the proposed amendments and explained how they ^{may} ~~could~~ distinguish the invention over prior art of record. The proposed claims include the language of "consisting essentially of" and Mr. Perez explained how those claims ^{may} ~~could~~ be more distinguished from prior art. The scope of claims, especially claim 1 was reviewed and Mr. Perez mentioned possible further limitation on these claims for clarity. The scope of "Basic medicine" was argued.

Examiner Note: You must sign this form unless it is an Attachment to a signed Office action.


Examiner's signature, if required

PRIVILEGED AND CONFIDENTIAL

Appl. Serial No. 09/380,310

November 18, 2003

Page 1 of 10

1. (Currently Amended) An oral medicine composition preventing an unpleasant taste, said medicine composition comprising:

~~which comprises a basic medicine having an unpleasant taste, an anionic polymer, and a filler.~~ taste and

an acidic polysaccharide,

wherein said acidic polysaccharide interacts with the basic medicine, and a bonding rate of said basic medicine to a receptor of a tongue decreases when dissolved in saliva.

2. (Currently Amended) The medicine composition according to Claim 1, wherein the ~~anionic polymer~~ acidic polysaccharide is at least one selected from the group consisting of carrageenan, chondroitin sulfate, dextran sulfate, alginic acid, gerun gum, xanthan gum and salts thereof. ~~and the filler is other than wax.~~

3. (Original) The medicine composition according to Claim 1 wherein the basic medicine having the unpleasant taste is an antibiotic substance, a dementia medicine, an antiplatelet medicine, an antidepressive medicine, a medicine for improving metabolism of a brain circulation, or an antiallergic medicine.

4. (Original) The medicine composition according to Claim 1 wherein the basic medicine having the unpleasant taste is donepezil hydrochloride.

PRIVILEGED AND CONFIDENTIAL

Appl. Serial No. 09/380,310

November 18, 2003

Page 2 of 10

5. (Canceled)

6. (Currently Amended) The medicine composition according to Claim 1, wherein the ~~anionic polymeric substance is contained~~ medicine composition comprises said acidic polysaccharide in an amount of 0.1 to 20 parts by weight with respect to 1 part by weight of the basic substance having the unpleasant taste.

7. (Original) The composition according to Claim 1 wherein the medicine is a granule medicine, a fine granule medicine, a powder medicine, a liquid medicine, a syrup medicine or a jelly medicine.

8. (Currently Amended) A method for preventing an unpleasant taste, said method comprising:

~~which comprises the step of blending an anionic polymer~~ acidic polysaccharide with a basic medicine having an unpleasant taste,

wherein said acidic polysaccharide interacts with the basic medicine, and a bonding rate of said basic medicine to a receptor of a tongue decreases when dissolved in saliva. and a filler.

9. (Currently Amended) The method according to claim 8, wherein the ~~anionic polymer~~ acidic polysaccharide is at least one selected from the group consisting of carrageenan, chondroitin sulfate,

PRIVILEGED AND CONFIDENTIAL

Appl. Serial No. 09/380,310

November 18, 2003

Page 3 of 10

dextran sulfate, alginic acid, gerun gum, xanthan gum and salts thereof.

10. (Previously Presented) The method according to claim 8 wherein the basic medicine having the unpleasant taste is an antibiotic, an antidementia medicine, an antiplatelet medicine, an antidepressive medicine, a medicine for improving metabolism of a brain circulation, or an antiallergic medicine.

11. (Previously Presented) The method according to claim 8 wherein the basic medicine having the unpleasant taste is donepezil hydrochloride.

12. (Canceled)

13. (Currently Amended) The method according to claim 8, wherein the ~~anionic polymer~~ acidic polysaccharide is contained in an amount of 0.1 to 20 parts by weight with respect to 1 part by weight of the basic substance having the unpleasant taste.

14. (Previously Presented) The method according to claim 8 wherein the medicine is granules, fine granules, powders, liquids, syrups or jellies.

PRIVILEGED AND CONFIDENTIAL

Appl. Serial No. 09/380,310

November 18, 2003

Page 4 of 10

15. (Currently Amended) An oral medicine composition preventing an unpleasant taste which comprises a blend of a basic medicine having an unpleasant taste and an ~~anionic-polymer-~~ acidic polysaccharide,

wherein said acidic polysaccharide interacts with the basic medicine, and a bonding rate of said basic medicine to a receptor of a tongue decreases when dissolved in saliva.

16. (Currently Amended) The medicine composition according to claim 15, wherein the ~~anionic-polymer~~ acidic polysaccharide is at least one selected from the group consisting of carrageenan, chondroitin sulfate, dextran sulfate, alginic acid, gerun gum, xanthan gum and salts thereof.

17. (Previously Presented) The medicine composition according to claim 15 wherein the basic medicine having the unpleasant taste is an antibiotic, an antidementia medicine, an antiplatelet medicine, an antidepressive medicine, a medicine for improving metabolism of a brain circulation, or an antiallergic medicine.

PRIVILEGED AND CONFIDENTIAL

Appl. Serial No. 09/380,310

November 18, 2003

Page 5 of 10

18. (Previously Presented) The medicine composition according to claim 15 wherein the basic medicine having the unpleasant taste is donepezil hydrochloride.

19. (Canceled)

20. (Currently Amended) The medicine composition according to claim 15, wherein the ~~anionic-polymer~~ acidic polysaccharide is contained in an amount of 0.1 to 20 parts by weight with respect to 1 part by weight of the basic substance having the unpleasant taste.

21. (Previously Presented) The medicine composition according to claim 15 wherein the medicine is granules, fine granules, powders, liquids, syrups or jellies.

22. (Currently Amended) An oral medicine preventing an unpleasant taste which comprises a basic medicine having an unpleasant taste, ~~a filler~~ and an ~~anionic-polymer~~, acidic polysaccharide,

wherein said acidic polysaccharide interacts with the basic medicine, and a bonding rate of said basic medicine to a receptor of a tongue decreases when dissolved in saliva;

PRIVILEGED AND CONFIDENTIAL

Appl. Serial No. 09/380,310

November 18, 2003

Page 6 of 10

~~wherein said anionic-polymer~~ acidic polysaccharide is at least one selected from the group consisting of carrageenan, chondroitin sulfate, dextran sulfate, alginic acid, gerun gum, xanthan gum and salts thereof;

said ~~anionic-polymer~~ acidic polysaccharide is in an amount of 0.1 to 20 parts by weight with respect to 1 part by weight of the basic substance having the unpleasant taste; ~~and~~

~~said filler is other than wax.~~ taste.

23. (Previously Presented) The medicine composition according to claim 22, wherein the basic medicine having the unpleasant taste is donepezil hydrochloride.

24. (Canceled)

25. (Currently Amended) A method for preventing an unpleasant taste which comprises the step of blending an ~~anionic-polymer~~ acidic polysaccharide with a basic medicine having an unpleasant taste, ~~and a filler,~~

wherein said acidic polysaccharide interacts with the basic medicine, and a bonding rate of said basic medicine to a receptor of a tongue decreases when dissolved in saliva;

~~wherein said anionic-polymer~~ acidic polysaccharide is at least one selected from the group consisting of carrageenan, chondroitin

PRIVILEGED AND CONFIDENTIAL

Appl. Serial No. 09/380,310

November 18, 2003

Page 7 of 10

sulfate, dextran sulfate, alginic acid, gerun gum, xanthan gum and salts thereof;

said ~~anionic-polymer~~ acidic polysaccharide is in an amount of 0.1 to 20 parts by weight with respect to 1 part by weight of the basic substance having the unpleasant ~~taste, and~~

~~said filler is other than wax.~~ taste.

26. (Previously Presented) The method according to claim 25, wherein the basic medicine having the unpleasant taste is donepezil hydrochloride.

27. (Canceled)

28. (Currently Amended) An oral medicine preventing an unpleasant taste which comprises a basic medicine having an unpleasant ~~taste, a filler other than wax, and an anionic polymer,~~ taste and an acidic polysaccharide;

wherein said acidic polysaccharide interacts with the basic medicine, and a bonding rate of said basic medicine to a receptor of a tongue decreases when dissolved in saliva;

~~wherein said anionic-polymer~~ acidic polysaccharide is at least one selected from the group consisting of chondroitin sulfate, dextran sulfate, alginic acid, gerun gum, xanthan gum and salts thereof, and

PRIVILEGED AND CONFIDENTIAL

Appl. Serial No. 09/380,310

November 18, 2003

Page 8 of 10

said ~~anionic-polymer~~ acidic polysaccharide is in an amount of 0.1 to 20 parts by weight with respect to 1 part by weight of the basic substance having an unpleasant taste.

29. (Currently Amended) An oral medicinal preparation consisting essentially of a basic medicine having an unpleasant taste, a filler and an ~~anionic-polymer,~~ acidic polysaccharide;

wherein said acidic polysaccharide interacts with the basic medicine, and a bonding rate of said basic medicine to a receptor of a tongue decreases when dissolved in saliva;

~~wherein said anionic-polymer~~ acidic polysaccharide is at least one selected from the group consisting of chondroitin sulfate, dextran sulfate, alginic acid, gerun gum, xanthan gum and salts thereof, and

said ~~anionic-polymer~~ acidic polysaccharide is in an amount of 0.1 to 20 parts by weight with respect to 1 part by weight of the basic substance having the unpleasant taste.

30. (Currently Amended) An oral medicinal preparation consisting of a basic medicine having an unpleasant taste, a filler and an ~~anionic-polymer,~~ acidic polysaccharide;

wherein said acidic polysaccharide interacts with the basic medicine, and a bonding rate of said basic medicine to a receptor of a tongue decreases when dissolved in saliva;

PRIVILEGED AND CONFIDENTIAL

Appl. Serial No. 09/380,310

November 18, 2003

Page 9 of 10

wherein said ~~anionic-polymer~~ acidic polysaccharide is at least one selected from the group consisting of chondroitin sulfate, dextran sulfate, alginic acid, gerun gum, xanthan gum and salts thereof, and

said ~~anionic-polymer~~ acidic polysaccharide is in an amount of 0.1 to 20 parts by weight with respect to 1 part by weight of the basic substance having the unpleasant taste.

31. (Previously Presented) The oral composition of Claim 1, wherein said filler is other than wax.

32. (Previously Presented) The method of claim 8, wherein said filler is other than wax.

33. (New) The oral medicinal preparation according to Claim 29, wherein the acidic polysaccharide is at least one selected from the group consisting of ι-carrageenan, κ-carrageenan, λ-carrageenan, dextran sulfate and a salt thereof.

34. (New) The medicine composition according to Claim 1, wherein the acidic polysaccharide is at least one selected from the group consisting of ι-carrageenan, κ-carrageenan, λ-carrageenan, dextran sulfate and a salt thereof.

PRIVILEGED AND CONFIDENTIAL

Appl. Serial No. 09/380,310

November 18, 2003

Page 10 of 10

35. (New) The oral medicinal preparation according to Claim 29, wherein the basic medicine is donepezil hydrochloride and said acidic polysaccharide is carrageenan.

36. (New) The medicine composition according to Claim 1, wherein the the basic medicine is donepezil hydrochloride and said acidic polysaccharide is carrageenan.

37. (New) A method for manufacturing an oral medicine composition comprising a basic medicine having an unpleasant taste and an acidic polysaccharide, said method comprising:

blending said acidic polysaccharide with said basic medicine,
and

producing said oral medicine composition;

wherein said acidic polysaccharide interacts with the basic medicine, and a bonding rate of said basic medicine to a receptor of a tongue decreases when dissolved in saliva;

said acidic polysaccharide is in an amount of 0.1 to 20 parts by weight with respect to 1 part by weight of the basic medicine; and

said acidic polysaccharide is at least one selected from the group consisting of carrageenan, chondroitin sulfate, dextran sulfate, alginic acid, gerun gum, xanthan gum and salts thereof.